Drug-risk communication to pharmacists: Assessing the impact of risk-minimization strategies on the practice of pharmacy

Journal of the American Pharmacists Association

Volumn 48, Issue 4, 2008, Pages 494-500

  Lee, Lauren Y ^a   Kortepeter, Cindy M ^a   Willy, Mary E ^a   Nourjah, Parivash ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Adverse drug effects; Black box warnings; Food and Drug Administration; Medication safety; Pharmacists; Risk management

Indexed keywords

DRUG;

ARTICLE; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY; PROFESSIONAL STANDARD; RISK MANAGEMENT; UNITED STATES;

COMMUNICATION; CROSS-SECTIONAL STUDIES; DATA COLLECTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; RISK MANAGEMENT; UNITED STATES;

EID: 53049100172     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2008.07045     Document Type: Article

References (10)

1. U.S. Food and Drug Administration. Medication guides. Accessed at www.fda.gov/cder/Offices/ODS/medication-guides.htm, March 30, 2007.
2. U.S. Food and Drug Administration. Guidance for industry development and use of risk minimization action plans. Accessed at www.fda.gov/cder/guidance/ 6358fnl.htm, October 13, 2006.
3. Hicks KE, Wogalter MS, Vigilante WJ. Placement of benefits and risks in prescription drug manufacturers' website and information source expectations. Drug Inf J. 2005;39:267-78.
4. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831-3.
5. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of "Dear Doctor" letters. Pharmacoepidemol Drug Saf. 2001;10:211-8.
6. Mazor KM, Andrade SE, Auger J, et al. Communicating safety information to physicians: an examination of Dear Doctor Letters. Pharmacoepidemol Drug Saf. 2005;14:869-75.
7. U.S. Food and Drug Administration, Department of Health and Human Services. 21 C.F.R. 208: Medication Guides for prescription drug products. 2006.
8. U.S. Food and Drug Administration, Department of Health and Human Services. 21 C.F.R. 208.3(a): defines an authorized dispenser as an individual licensed, registered, or otherwise permitted by the jurisdiction in which the individual practices to provide drug products on prescriptions in the course of professional practice. 2006.
9. U.S. Food and Drug Administration, Department of Health and Human Services. 21 C.F.R. 208.24 (distributing and dispensing a Medication Guide) and 208.26 (exemptions and deferrals). 2006.
10. Svarstad B, Mount J, Tabek E. Expert and consumer evaluation of patient medication leaflets provided in US pharmacies. J Am Pharm Assoc. 2005;45:443-51.